Blueprint Medicines Corporation Profile Avatar - Palmy Investing

Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (S…
Biotechnology
US, Cambridge [HQ]

Balance Sheet

11 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Assets
4.00 49.00 178.00 282.00 715.00 540.00 707.00 1,718.00 1,252.00 1,349.00 1,049.00
Current
2.00 48.00 170.00 220.00 685.00 499.00 516.00 927.00 554.00 1,046.00 808.00
Non Current
1.00 1.00 8.00 62.00 30.00 40.00 190.00 790.00 698.00 303.00 240.00
Liabilities
5.00 14.00 34.00 69.00 91.00 121.00 243.00 248.00 281.00 835.00 918.00
Current
3.00 6.00 18.00 28.00 42.00 60.00 106.00 130.00 149.00 183.00 214.00
Non Current
2.00 7.00 16.00 41.00 48.00 60.00 136.00 117.00 131.00 651.00 703.00
Equity
-1.00 35.00 143.00 213.00 623.00 419.00 464.00 1,470.00 970.00 514.00 130.00
Stockholders' Equity
-1.00 35.00 143.00 213.00 623.00 419.00 464.00 1,470.00 970.00 514.00 130.00
Retained Earnings
-41.00 -82.00 -134.00 -207.00 -355.00 -597.00 -945.00 -631.00 -1,275.00 -1,832.00 -2,339.00
Common Stock
- - - - - - - - - - - - - - - - - - - - - -
Preferred Stock
39.00 114.00 178.00 - - - - - - - - - - - - - - - -
Profit
-20.00 -40.00 -52.00 -72.00 -148.00 -236.00 -328.00 313.00 -644.00 -557.00 -506.00
Dividends
- - - - - - - - - - - - - - - - - - - - - -
Minority Interest
- - - - - - - - - - - - - - - - - - - - - -
Other Stockholders' Equity
1.00 4.00 102.00 420.00 979.00 1,016.00 1,412.00 2,106.00 2,250.00 2,358.00 2,473.00
Loss Other Compr. Income
- - -1.00 -2.00 - - - - - - -2.00 -5.00 -4.00 -10.00 -3.00
End of BPMC's Analysis
CIK: 1597264 CUSIP: 09627Y109 ISIN: US09627Y1091 LEI: - UEI: -
Secondary Listings
BPMC has no secondary listings inside our databases.